ArticleFrontiers in oncology2026
Distinguishing granulomatous lobular mastitis from breast cancer using a clinical-radiomics nomogram to improve diagnostic accuracy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Granulomatous lobular mastitis (GLM) is often misdiagnosed clinically as breast cancer (BC). Therefore, it is crucial to differentiate between GLM and BC. Methods: This study used 259 samples from 129 patients with GLM and 130 with BC. A total of 874 radiomics and 11 clinical features were obtained. The least absolute shrinkage and selection operator algorithm was used to select radiomics features. Univariate and multivariate analyses were performed to screen clinical features. Three machine learning algorithms were applied to assess the efficiency of the radiomics, clinical, and combined models, which were compared to select the optimal model. Finally, a nomogram based on the optimal model was developed. Decision curve analysis (DCA) and calibration curves were used to assess the clinical utility of the nomogram. Results: Twelve radiomics features were identified as the most relevant for distinguishing GLM from BC, including the original gray level co-occurrence matrix autocorrelation feature. Important clinical features included age, nipple inversion, and C-reactive protein levels. The combined model demonstrated superior performance in terms of accuracy, specificity, and sensitivity compared with the clinical and radiomics models. A nomogram was constructed based on the combined model. The calibration curve and DCA further confirmed the superior clinical value of the nomogram. Conclusion: A combined model incorporating 12 radiomics and 3 clinical features is potentially valuable for distinguishing GLM from BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.